Monotherapy, in the form of
amphotericin B or one of its liposomal derivatives, is the usual treatment for
invasive fungal infections, due to lack of a safe, effective combination of antifungal drugs. Combination
therapy is not necessarily beneficial-there may be mutual antagonism or indifference, increased toxicity or interference with concomitant medication. But the benefits of a well-tolerated, synergistic combination would be great-the enhanced efficacy would improve clinical outcome, reduce the need for prolonged courses of treatment and prevent the emergence of antifungal drug resistance. Antifungal
antibodies would be a natural partner in a combinatorial approach to antifungal
therapy. Analysis of the antibody response which occurs in patients with
invasive candidiasis, being treated with
amphotericin B, showed a close correlation between recovery and antibody to the immunodominant
heat shock protein 90 (hsp90). The
molecular chaperone hsp90 is essential for yeast viability.
Mycograb is a human recombinant antibody to hsp90 which shows intrinsic antifungal activity and synergy with
amphotericin B both in vitro and in vivo. It is now the subject of a multinational, double-blind, placebo-controlled trial, in patients with culture-confirmed
invasive candidiasis on
liposomal amphotericin B.